Xeris Pharmaceuticals, Inc discovered novel Gvoke HypoPen™ (glucagon injection),which is used for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above. The speciality of Gvoke HypoPen premixed autoinjector is that it consists of no visible needle.
Gvoke HypoPen™, the first autoinjector a reliable method of glucagon delivery proven to work effectively, easy to use which is available now in the market.
Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle available in two doses: 0.5 mg/0.1 mLfor children (weighing less than 100 pounds) and 1 mg/0.2 mL for adolescents and adults (weighing 100 pounds or greater).
Gvoke HypoPen™ autoinjector is easy to use and assures 99 per cent of adults and 100 per cent of kids to have their blood sugars raised to safe levels.
Few of the common side effects caused by GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.
GvokeHypoPen™, the First Autoinjector is now available in US for the treatment of severe hypoglycemia in adults and children withdiabetes ages 2 years and above.
